Novel Molecular and Genetic Therapies for Inherited Arrhythmia Syndrome and Arrhythmogenic Cardiomyopathies

Inherited arrhythmia syndromes and cardiomyopathies pose a significant clinic challenge, with suboptimal treatment and a large unmet need. Over the last decade several new therapies have been developed which target the underlying genetic and molecular causes of these conditions, and many are progressing from pre-clinical research to clinical trials. These discoveries offer a potential paradigm shift in treatment strategies and quality of life for patients. This panel focused on novel genetic and molecular therapies for inherited arrhythmia syndromes and arrhythmogenic cardiomyopathies will bring together experts with a broad range of experience including venture capital, clinicians, translational scientists, and biotech. The session will address a wide range of topics from lab discovery to commercialization.